^
    Apply
    Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT01989598)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    03/02/2022
    Initiation :
    10/30/2013
    Primary completion :
    08/31/2019
    Completion :
    09/28/2020
    BRAF
    |
    Mekinist (trametinib) • uprosertib (LAE003)
    Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer (NCT01935973)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/14/2020
    Initiation :
    09/30/2013
    Primary completion :
    09/08/2015
    Completion :
    09/08/2015
    KRAS
    |
    KRAS mutation • KRAS wild-type
    |
    Mekinist (trametinib) • uprosertib (LAE003)
    Trametinib With GSK2141795 in BRAF Wild-type Melanoma (NCT01941927)
    Phase 2
    Adil Daud
    Completed
    Last update posted :
    02/12/2020
    Initiation :
    09/10/2013
    Primary completion :
    10/14/2014
    Completion :
    05/03/2017
    BRAF • NRAS
    |
    BRAF mutation • NRAS mutation • BRAF wild-type • RAS wild-type • NRAS wild-type
    |
    Mekinist (trametinib) • uprosertib (LAE003)
    Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290 (NCT02093546)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    01/28/2020
    Initiation :
    08/13/2004
    Primary completion :
    01/15/2020
    Completion :
    01/15/2020
    BRAF
    |
    Mekinist (trametinib) • uprosertib (LAE003)
    Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer (NCT01964924)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    09/20/2019
    Initiation :
    10/02/2013
    Primary completion :
    01/20/2017
    Completion :
    04/23/2018
    HER-2 • ER • PGR
    |
    Mekinist (trametinib) • uprosertib (LAE003)
    Safety, Pharmacokinetics (PK) of AKT and MEK Combination (NCT01138085)
    Phase 2
    GlaxoSmithKline
    Completed
    Last update posted :
    11/13/2017
    Initiation :
    05/04/2010
    Primary completion :
    11/19/2014
    Completion :
    11/19/2014
    HER-2 • KRAS • BRAF • ER • PGR • PTEN
    |
    KRAS mutation • BRAF mutation • BRAF wild-type
    |
    Mekinist (trametinib) • uprosertib (LAE003)
    A Study of Trametinib and GSK2141795 Multiple Myeloma (NCT01951495)
    Phase 2
    University Health Network, Toronto
    Not yet recruiting
    Last update posted :
    11/06/2017
    Initiation :
    10/01/2013
    Primary completion :
    10/01/2015
    Completion :
    03/01/2016
    BRAF
    |
    Mekinist (trametinib) • uprosertib (LAE003)